HC Wainwright Brokers Increase Earnings Estimates for RMTI

Rockwell Medical, Inc. (NASDAQ:RMTI) – Investment analysts at HC Wainwright increased their FY2025 earnings estimates for shares of Rockwell Medical in a note issued to investors on Monday, January 26th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.09) for the year, up from their previous estimate of ($0.17). HC Wainwright currently has a “Buy” rating and a $2.50 target price on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is $0.03 per share. HC Wainwright also issued estimates for Rockwell Medical’s Q4 2025 earnings at $0.04 EPS, Q1 2026 earnings at ($0.01) EPS, Q2 2026 earnings at ($0.01) EPS and FY2026 earnings at ($0.03) EPS.

Several other brokerages have also recently commented on RMTI. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rockwell Medical in a research note on Thursday, January 22nd. Wall Street Zen downgraded shares of Rockwell Medical from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Rockwell Medical currently has an average rating of “Hold” and an average price target of $2.50.

Rockwell Medical Stock Performance

Shares of RMTI stock opened at $1.15 on Wednesday. The company has a current ratio of 3.91, a quick ratio of 3.50 and a debt-to-equity ratio of 0.25. The stock has a 50 day simple moving average of $0.94 and a 200-day simple moving average of $1.11. The company has a market cap of $45.31 million, a price-to-earnings ratio of -7.19 and a beta of 1.65. Rockwell Medical has a 12-month low of $0.78 and a 12-month high of $2.15.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in Rockwell Medical by 12.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock worth $1,625,000 after acquiring an additional 148,737 shares during the period. GSA Capital Partners LLP grew its position in shares of Rockwell Medical by 635.1% in the third quarter. GSA Capital Partners LLP now owns 163,978 shares of the company’s stock valued at $197,000 after purchasing an additional 141,672 shares during the period. Finally, Panagora Asset Management Inc. acquired a new position in Rockwell Medical in the second quarter valued at $41,000. 23.31% of the stock is currently owned by hedge funds and other institutional investors.

About Rockwell Medical

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.